Wednesday, August 20, 2025 8/20/2025

Continuum of Immune Responses to Cryptococcus neoformans

Award Number: R01AI176922
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/06/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Continuum of Immune Responses to Cryptococcus neoformans - Abstract Cryptococcal meningitis (CM), caused by the fungal pathogen Cryptococcus neoformans (Cn), is among the most prevalent HIV/AIDS-associated opportunistic infections and causes 15% of AIDS- related mortality globally. In healthy individuals, exposure to Cn in early childhood results in a pulmonary latent infection that is asymptomatic, but leads to the formation of lung granulomas. Following HIV-associated compromise of the immune system, control of latent Cn infection within pulmonary granulomas is lost and the fungus disseminates to cause meningitis. Most studies examining host-pathogen interactions in Cn are observational studies in human cohorts or analyze reference Cn strains in acute disease models of cryptococcosis. We recently showed that the mouse model accurately recapitulates differences in human survival that are observed across Cn clinical isolates and used these data to develop a mouse model of latent Cn infection. Our preliminary data using these mouse models to analyze the immune response to over 50 Cn clinical isolates from individuals with advanced HIV revealed a continuum of disease outcomes that we classified into 3 groups: 1) latent infection resulting in granuloma formation and control; 2) lethal disease similar to that observed with Cn reference strains; and 3) hypervirulence resulting in rapid mortality. Previous studies with reference strains revealed lethal disease is associated with various Cn virulence factors and a detrimental host Th2-mediated type-2 immune response. In contrast, disease prevention is associated with the type-1 cytokine IFNγ. How these Cn-host interactions differ to cause the continuum of disease observed in immunocompromised individuals with HIV is not well defined. We will use analysis of clinical isolates in mouse models of disease to test our central hypothesis that antigenic differences between Cn clinical isolates lead to either protective or detrimental immune responses in the host. We will test this hypothesis by pursuing three specific aims. Our first and second aims will determine the host cellular and effector functions that result in either latency (Aim 1), lethal disease (control infections), or hypervirulence (Aim 2). Our third aim will identify Cn gene alleles for antigens that influence the immune response and ultimately disease outcome. Taken together, these translational studies will define the molecular processes underlying the continuum of Cryptococcus disease with the goal of developing novel immune-modulatory treatment strategies for at-risk patient populations.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $765,843 )
2025	2025	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Allergy and Infectious Diseases Research	002	4	4/11/2025	NON-COMPETING CONTINUATION	$765,843
2025	2024	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Allergy and Infectious Diseases Research	000	2	4/3/2025	NON-COMPETING CONTINUATION	-$69,521
2025	2024	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Allergy and Infectious Diseases Research	001	3	4/3/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$69,521
														Subtotal = $765,843

Issue Date FY: 2024 ( Subtotal = $755,169 )
2024	2024	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Allergy and Infectious Diseases Research	002	2	8/1/2024	NON-COMPETING CONTINUATION	-$461,559
2024	2024	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Allergy and Infectious Diseases Research	001	2	5/23/2024	NON-COMPETING CONTINUATION	$73,730
2024	2024	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Allergy and Infectious Diseases Research	000	2	3/12/2024	NON-COMPETING CONTINUATION	$663,572
2024	2024	VIRGINIA POLYTECHNIC INSTITUTE & STATE UNIVERSITY	300 TURNER ST NW	BLACKSBURG	VA	24060	MONTGOMERY	USA	Allergy and Infectious Diseases Research	003	3	8/1/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$479,426
														Subtotal = $755,169

Issue Date FY: 2023 ( Subtotal = $737,302 )
2023	2023	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE # 224	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Allergy and Infectious Diseases Research	000	1	4/5/2023	NEW	$737,302
														Subtotal = $737,302

Grand Total All Awards = $2,258,314

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Continuum of Immune Responses to Cryptococcus neoformans

Award Number: R01AI176922

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/06/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer